Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller ...

If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Low Risk Penny Stocks to Buy Now. On February 27, Bank of America ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.44, moving -1.99% from the previous trading session. This change lagged the S&P 500's 0.21% loss on the day. Meanwhile, the ...

Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...

Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...